Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy

Journal of Immunotherapy

Volumn 20, Issue 5, 1997, Pages 372-376

  Doran, Trisha ^a   Stuhlmiller, Heidi ^a   Kim, Julian A ^a   Martin, Edward W ^a   Triozzi, Pierre L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adoptive immunotherapy; C myc; Interleukin 1; Interleukin 2; Ras; Transforming growth factor 1

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 8; MACROPHAGE CHEMOTACTIC FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESEARCH; GENE OVEREXPRESSION; HUMAN; METASTASIS; ONCOGENE C MYC; ONCOGENE RAS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031451835     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199709000-00006     Document Type: Article

References (27)

1. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohisto chemical correlates of interleukin-2-based response to recombinant immunotherapy in humans. Cancer Res 1989;49:7086-92.
2. Ransom JH, Pelle B, Hanna MG. Expression of class II major histocompatibility complex molecules correlates with human colon tumor vaccine efficacy. Cancer Res 1992;52:3460-6.
3. Torigoe T, Sato N, Takashima T, et al. Tumor rejection antigens on BALB/c cells transformed by activated oncogenes. J Immunol 1991;147:3251-68.
4. Parmiani G, Anichini A, Carbone G, Sensi M. Can oncogene (ras) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy. Melanoma Res 1991;2:123-5.
5. Frey AB, Cestari S. Expression of activated H-rasval12 in nontu morigenic and non-cross-reactive syngeneic cells induces tumor antigens cross-reactive with rat mammary adenocarcinoma 13762. J Immunol 1995;155:4783-9.
6. Triozzi PL, Benzies T, Kim JA, Martin EW, Villasmil P. Phase lb trial of interleukin-1β and interleukin-2 in patients with metastatic cancer. J Clin Oncol 1995;13:482-9.
7. Triozzi PL, Kim J, Martin EW. Adoptive immunotherapy using lymph node lymphocytes localized in vivo with radiolabeled monoclonal antibody. J Natl Cancer Inst 1995;87:1180-1.
8. Triozzi PL, Kim JA, Aldrich WA, Young D, Sampsel J, Martin EW. Identification of tumor-reacting lymph node lymphocytes in vivo using radiolabeled monoclonal antibody. Cancer 1994; 73: 580-9.
9. Hardingham J, Kotasek D, Farmer B, et al. Immunobead-PCR: A technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res 1993;53:3455-8.
10. Ciolli V, Gabriele L, Sestili P, et al. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established métastasés. J Exp Med 1991;173:313-22.
11. Vogelstein B, Fearon E, Hamilton S, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
12. Benhattar J, Losi L, Chaubert P, Givel J-C, Costa J. Prognostic significance of k-ras mutation in colorectal carcinoma. Gastroenterology 1993;104:1044-8.
13. Finkelstein S, Sayegh R, Christensen S, Swalsky P. Genotypic classification of colorectal adenocarcinoma. Cancer 1993; 71: 3827-38.
14. Kern S, Fearon E, Tersmette K, et al. Allelic loss in colorectal carcinoma. JAMA 1991;261:3099-103.
15. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
16. Bell S, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutation in colorectal cancer. Gastroenterology 1993;104:57-64.
17. Markowitz S, Hines JD, Lutterbaugh J, et al. Mutant K-ras oncogenes in colon cancers do not predict patient’s chemotherapy response or survival. Clin Cancer Res 1995;1:441-5.
18. Erisman MD, Litwin S, Keichan RD, Comis RL, Astrin SM. Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of the disease or patient survival. Cancer Res 1988;48:1350-5.
19. Tsuboi K, Hirayoshi K, Takeuchi K, et al. Expression of c-myc gene in human gastrointestinal malignancies. Biochem Biophys Res Commun 1987;146:699-794.
20. Smith DR, Goh H-S. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res 1996;2:1049-53.
21. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93:2909-14.
22. Naylor MS, Stamp GWH, Balkwill FR. Investigation of cytokine gene expression in human colorectal cancer. Cancer Res 1990;50: 4436.
23. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4:549-54.
24. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
25. Barth RJ, Camp BJ, Maruscello TA, Dain BJ, Memoli VA. The cytokine microenvironment of human colon carcinoma: Lymphocyte expression of tumor necrosis factor-α and interleukin-4 predicts improved survival. Cancer 1996;78:1168-78.
26. Castelli C, Sensi M, Lupetti R, et al. Expression of interleukin la, interleukin 6, and tumor necrosis factor in human melanoma clones is associated with that of mutated N-ras oncogene. Cancer Res 1994;54:4785-90.
27. Osband ME, Lavin PT, Babayan RK, et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990;335:994-8.